During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines’ Ayvakit ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

DelveInsight’s, “Systemic Mastocytosis Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and ...

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

Corticosteroid drugs to help ease inflammation are the first-line treatment for Sweet's syndrome, although other options are available. Mastocytosis happens when white blood cells called mast cells ...

Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant’s fourth major strategic acquisition ...

Novel diagnosis and treatment approaches for mastocytosis in the skin (MIS), a condition that may indicate underlying systemic mastocytosis (SM), have been outlined in a new clinical review published ...

Blueprint specializes in systemic mastocytosis and other diseases driven by KIT, a receptor on mast cells. Blueprint’s most recently approved drug is Ayvakit, which the US Food and Drug ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.